Squamous Cell Cancer of the Oral Cavity

1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).

Anti-tumor B

Placebos taken seven to 28 days (dependent on scheduled surgery).

Placebos

Inhibition of Oral Tumorigenesis by Antitumor B

KI-67 will be measured as a change in the index from baseline to post-treatment (surgery).

The AUC will be calculated using software. The calculation will be mg/ml X hour.

The Cmax will be calculated using software. The calculation will be ng/ml.

The effect of ATB NF-ĸB signaling pathway will be examined by expression of target genes (cyclin D1 and B-cell lymphoma-extra large (BCL-XL)).

RNA Seq will be performed to identify gene expression signatures to identify genes that may predict for responsiveness or resistance to treatment.

Stuart Wong

Professor

Medical College of Wisconsin

In good general health and feeling well (no diagnosed disorders/illnesses)
At least 18 years old
BMI in the range of 18-29.9 kg/m²
No known history of substance abuse
No known allergies to food/drug

Healthy Adults

Antitumor B

Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 1 of 3

Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 2 of 3

Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 3 of 3

ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia

University of Houston, College of Pharmacy

Pharmacokinetics Study of Antitumor B in Healthy Volunteers

Maximum (peak) observed drug concentration in plasma

Maximum (peak) observed drug concentration in saiva

Time of Maximum (peak) observed drug concentration in plasma

Time of Maximum (peak) observed drug concentration in saliva

Area under the curve of plasma concentration-time profile

Area under the curve of saliva concentration-time profile

In vivo-in vivo correlation established between plasma and saliva concentrations

Ming Hu

University of Houston

Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule

Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule

Prostatic Neoplasms

METFORMIN

Placebo

TAXOTERE®

Centre ANTOINE LACASSAGNE

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer

A Multicentric, Randomized, Phase II Study Evaluating the Combination of METFORMIN With TAXOTERE®+Metformine Placebo Versus TAXOTERE®+Metformin for the Treatment of Metastatic Hormone-refractory Prostate Cancer.

dioscorea spiculiflora/antikancerogena

Inhibition of Oral Tumorigenesis by Antitumor B

Pharmacokinetics Study of Antitumor B in Healthy Volunteers

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer

Najkompletnija baza ljekovitog bilja potpomognuta naukom